ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
4:00 PM ET on Apr 17, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Mar 27, 2014
ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology
Mar 13, 2014
ChemoCentryx Announces Financial Results for the Quarter and Year Ended December 31, 2013
Mar 3, 2014
ChemoCentryx to Hold Fourth Quarter and Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
^ Return to Top